Yanxia X. Wang

Henan Key Laboratory Of Infectious Pathogenic Microbiology
Zhengzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Immunogenicity and safety of primary three-dose series with diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed in 3 months infants.

Immunogenicity and safety of primary three-dose series with diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed in 3 months infants.

Journal: Frontiers in immunology

Published: May 07, 2026

Safety and immunogenicity of diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed after three-dose priming in 2 months age infants: a randomized, blinded, controlled phase III clinical trial in China.

Safety and immunogenicity of diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed after three-dose priming in 2 months age infants: a randomized, blinded, controlled phase III clinical trial in China.

Journal: Emerging microbes & infections

Published: January 30, 2026

Correction: Wang et al. Immune Persistence Following a Single Dose of Varicella Vaccine: 5-Year and 8-Year Follow-Up of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Vaccines 2025, 13, 1024.

Correction: Wang et al. Immune Persistence Following a Single Dose of Varicella Vaccine: 5-Year and 8-Year Follow-Up of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Vaccines 2025, 13, 1024.

Journal: Vaccines

Published: December 10, 2025

The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in 12-23-Month Children: A Double-Blind, Randomized, Phase III Trial in China.

The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in 12-23-Month Children: A Double-Blind, Randomized, Phase III Trial in China.

Journal: Vaccines

Published: October 28, 2025

Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial.

Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial.

Journal: BMC infectious diseases

Published: September 10, 2025

Immune Persistence Following a Single Dose of Varicella Vaccine: 5-Year and 8-Year Follow-Up of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial.

Immune Persistence Following a Single Dose of Varicella Vaccine: 5-Year and 8-Year Follow-Up of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial.

Journal: Vaccines

Published: August 07, 2025

Safety and Immunogenicity of Single-Dose of Adsorbed Tetanus Vaccine in Adults Aged 18-44 Years: Randomized, Double-Blind, Positive-Controlled Phase I/III Clinical Trial.

Safety and Immunogenicity of Single-Dose of Adsorbed Tetanus Vaccine in Adults Aged 18-44 Years: Randomized, Double-Blind, Positive-Controlled Phase I/III Clinical Trial.

Journal: Vaccines

Published: August 06, 2025

Correction: Huang et al. The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6-35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial. Vaccines 2025, 13, 467.

Correction: Huang et al. The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6-35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial. Vaccines 2025, 13, 467.

Journal: Vaccines

Published: July 22, 2025

Immune persistence of a single dose of 23-valent pneumococcal polysaccharide vaccine: A 6-year follow-up.

Immune persistence of a single dose of 23-valent pneumococcal polysaccharide vaccine: A 6-year follow-up.

Journal: Human vaccines & immunotherapeutics

Published: June 19, 2025

Safety and Immunogenicity of a New Rotavirus-Inactivated Vaccine in the Chinese Adolescent Population: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial.

Safety and Immunogenicity of a New Rotavirus-Inactivated Vaccine in the Chinese Adolescent Population: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial.

Journal: Vaccines

Published: February 17, 2025

The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6-35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial.

The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6-35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial.

Journal: Vaccines

Published: February 08, 2025

Safety and immunogenicity of full-dose quadrivalent influenza vaccine in children 6-35 months of age in China: A randomized, double-blind, clinical trial.

Safety and immunogenicity of full-dose quadrivalent influenza vaccine in children 6-35 months of age in China: A randomized, double-blind, clinical trial.

Journal: Human vaccines & immunotherapeutics

Published: November 14, 2024

Showing 1-12 of 37

Last Updated: 09/26/2026